Abstract
Autoimmune type 1 diabetes is strongly associated with a number of immune abnormalities that manifest themselves before and at the time of clinical diagnosis. The clinical onset is associated with a major loss of the pancreatic islet beta cells. Insulin treatment is the only treatment option since numerous trials with agents that suppress or modulate immune function have failed to preserve beta cell function long term. Recent studies suggest that it is possible to predict clinical onset of diabetes by combining genetic with autoantibody testing. In this review we will summarize current and future drug targets for subjects at risk for type 1 diabetes as well as for subjects with recent onset disease. We will also discuss the possible importance of initiating as well as contributing factors such as reactive oxygen species and modified autoantigens. It is speculated that drug targets of factors important to disease pathogenesis may provide safe and effective adductive treatment to preserve beta cell function in autoantibody positive subjects who are at maximum risk for disease.
Keywords: variable number tandem repeat (VNTR), CTLA-4, Viral infections, Cadmium, Oxidative Stress, antioxidant
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Targeting Type 1 Diabetes Before and at the Clinical Onset of Disease
Volume: 6 Issue: 1
Author(s): L. M. Bekris, T. J. Kavanagh and A. Lernmark
Affiliation:
Keywords: variable number tandem repeat (VNTR), CTLA-4, Viral infections, Cadmium, Oxidative Stress, antioxidant
Abstract: Autoimmune type 1 diabetes is strongly associated with a number of immune abnormalities that manifest themselves before and at the time of clinical diagnosis. The clinical onset is associated with a major loss of the pancreatic islet beta cells. Insulin treatment is the only treatment option since numerous trials with agents that suppress or modulate immune function have failed to preserve beta cell function long term. Recent studies suggest that it is possible to predict clinical onset of diabetes by combining genetic with autoantibody testing. In this review we will summarize current and future drug targets for subjects at risk for type 1 diabetes as well as for subjects with recent onset disease. We will also discuss the possible importance of initiating as well as contributing factors such as reactive oxygen species and modified autoantigens. It is speculated that drug targets of factors important to disease pathogenesis may provide safe and effective adductive treatment to preserve beta cell function in autoantibody positive subjects who are at maximum risk for disease.
Export Options
About this article
Cite this article as:
Bekris M. L., Kavanagh J. T. and Lernmark A., Targeting Type 1 Diabetes Before and at the Clinical Onset of Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (1) . https://dx.doi.org/10.2174/187153006776056576
DOI https://dx.doi.org/10.2174/187153006776056576 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Reactive Species, Cellular Repair and Risk Factors in the Onset of Type 2 Diabetes Mellitus: Review and Hypothesis
Current Diabetes Reviews Epidemiology of Diabetes Mellitus in the United Arab Emirates
Current Diabetes Reviews Biologic Agents for Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advanced Glycation End Products as Environmental Risk Factors for the Development of Type 1 Diabetes
Current Drug Targets Management of Type-1 and Type-2 Diabetes by Insulin Injections in Diabetology Clinics - A Scientific Research Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cell Immunity in Inflammatory Vasculitis
Current Immunology Reviews (Discontinued) Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Vaccines For Type 1 Diabetes: Prevention or Reversal?
Current Diabetes Reviews Curcumin as an Adjuvant to Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology Adeno-Associated Virus Vectors: Immunobiology and Potential Use for Immune Modulation
Current Gene Therapy HCV-Related Rheumatic Manifestations and Therapeutic Strategies
Current Drug Targets Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis
Current Topics in Medicinal Chemistry Molecular Damage in Glaucoma: from Anterior to Posterior Eye Segment. The MicroRNA Role
MicroRNA The Role of the Immune System in the Pathogenesis of Hypertension
Current Hypertension Reviews Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets